loading
Syndax Pharmaceuticals Inc stock is traded at $9.63, with a volume of 1.27M. It is down -3.60% in the last 24 hours and up +8.20% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$9.99
Open:
$10
24h Volume:
1.27M
Relative Volume:
0.59
Market Cap:
$828.64M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-3.2534
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+1.80%
1M Performance:
+8.20%
6M Performance:
-32.42%
1Y Performance:
-60.90%
1-Day Range:
Value
$9.55
$10.00
1-Week Range:
Value
$9.38
$10.50
52-Week Range:
Value
$8.58
$25.07

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
Name
Syndax Pharmaceuticals Inc
Name
Phone
781-419-1400
Name
Address
730 THIRD AVENUE, NEW YORK, MA
Name
Employee
184
Name
Twitter
@syndax
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
SNDX's Discussions on Twitter

Compare SNDX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SNDX
Syndax Pharmaceuticals Inc
9.63 859.61M 139.71M -209.36M -160.60M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Initiated Goldman Buy
Oct-24-24 Initiated UBS Buy
Jun-28-24 Initiated Jefferies Buy
Jan-31-24 Downgrade Scotiabank Sector Outperform → Sector Perform
Dec-22-23 Initiated Mizuho Buy
Oct-25-23 Initiated BofA Securities Buy
Oct-11-23 Initiated Goldman Buy
Jul-27-23 Initiated Scotiabank Sector Outperform
Jul-11-23 Initiated Guggenheim Buy
Apr-17-23 Resumed BTIG Research Buy
Jan-31-23 Initiated Stifel Buy
Jan-03-23 Initiated JP Morgan Overweight
Jul-28-22 Resumed B. Riley Securities Buy
Apr-11-22 Initiated H.C. Wainwright Buy
Feb-15-22 Initiated Goldman Buy
Jun-04-21 Resumed Robert W. Baird Outperform
May-25-21 Initiated Citigroup Buy
Feb-18-21 Initiated B. Riley Securities Buy
Dec-03-20 Initiated Stifel Buy
May-22-20 Upgrade Citigroup Neutral → Buy
May-22-20 Downgrade H.C. Wainwright Buy → Neutral
May-18-20 Downgrade Citigroup Buy → Neutral
May-11-20 Reiterated H.C. Wainwright Buy
Mar-04-20 Initiated Barclays Overweight
Jan-13-20 Reiterated H.C. Wainwright Buy
Mar-08-19 Reiterated H.C. Wainwright Buy
Jan-04-19 Initiated Robert W. Baird Outperform
Jan-05-18 Initiated B. Riley FBR, Inc. Buy
Mar-16-17 Initiated FBR & Co. Outperform
Mar-02-17 Initiated Instinet Buy
Oct-07-16 Initiated Guggenheim Buy
Mar-28-16 Initiated Citigroup Buy
Mar-28-16 Initiated JMP Securities Mkt Outperform
Mar-28-16 Initiated Morgan Stanley Overweight
View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

pulisher
Jul 25, 2025

Is Syndax Pharmaceuticals Inc. a good long term investmentRecord-setting profit potential - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about Syndax Pharmaceuticals Inc. stockRapid market gains - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Should I buy Syndax Pharmaceuticals Inc. stock before earningsGame-changing capital returns - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

What drives Syndax Pharmaceuticals Inc. stock priceDynamic capital growth - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613 - TipRanks

Jul 24, 2025
pulisher
Jul 23, 2025

Syndax Pharmaceuticals Inc. Stock Analysis and ForecastDouble-digit growth - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CFO Keith A. Goldan Sells 1,296 Shares - MarketBeat

Jul 22, 2025
pulisher
Jul 22, 2025

Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group Acquires New Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jul 22, 2025
pulisher
Jul 21, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Sells $69,990.86 in Stock - MarketBeat

Jul 21, 2025
pulisher
Jul 20, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Teacher Retirement System of Texas - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $34.10 - MarketBeat

Jul 19, 2025
pulisher
Jul 19, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Cut to $35.00 by Analysts at UBS Group - MarketBeat

Jul 19, 2025
pulisher
Jul 18, 2025

Top Executives at Syndax Pharmaceuticals Make Significant Stock Moves! - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

Syndax Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView

Jul 18, 2025
pulisher
Jul 18, 2025

Is Syndax Pharmaceuticals Inc. stock a good hedge against inflationFree Insider Trading Tips - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Will Syndax Pharmaceuticals Inc. stock benefit from interest rate changesBreakout Confirmation Tool - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

(SNDX) Trading Advice - news.stocktradersdaily.com

Jul 18, 2025
pulisher
Jul 17, 2025

UBS Group Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6% on Analyst Downgrade - Defense World

Jul 16, 2025
pulisher
Jul 16, 2025

Syndax CFO and CEO sell shares at $9.29/share on July 16, 2025. - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Syndax’s Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML - MSN

Jul 15, 2025
pulisher
Jul 15, 2025

Why Syndax Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 6% on Analyst Downgrade - MarketBeat

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Syndax Pharmaceuticals Inc. stock price move sharplyPro Trader Stock Focus - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

UBS Lowers Price Target for Syndax Pharmaceuticals (SNDX) to $35 - GuruFocus

Jul 15, 2025

Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):